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Background:  We evaluated the effect and safety of the immediate postoperative continuous infusion of remifentanil 
at two doses in patients undergoing laparoscopic-assisted vaginal hysterectomy (LAVH) with alfentanil-based 
patient-controlled analgesia (PCA).
Methods:  The study enrolled 50 ASA physical status 1 or 2 patients scheduled to undergo LAVH.  Anesthesia was 
maintained with sevoflurane-remifentanil-air. At the last skin suture, the sevoflurane was discontinued, and patients 
were randomized to receive remifentanil 0.05 μg/kg/min (group I) or 0.1 μg/kg/min (group II).  PCA was started at 
the time of eye opening and response to a verbal command. In the recovery room, we monitored the mean arterial 
blood pressure (MAP), heart rate (HR), respiratory rate (RR), SpO2, and bispectral index (BIS) at 5-minute intervals. 
Thirty minutes after starting PCA, the remifentanil was discontinued.  Pain was assessed using a visual analog scale (0 
= no pain; 100 = the worst possible pain) at 0, 5, 10, and 30 minutes after stopping the remifentanil infusion.
Results:  The eye opening time, BIS, MAP, and HR did not differ significantly between the two groups, and pain scores 
were similar between the two groups.  Respiratory depression (SpO2 < 90% or RR < 8/min) did not occur in group I 
but did occur in three patients in group II.
Conclusions:  Continuous remifentanil infusion (0.05 μg/kg/min) immediately postoperatively with alfentanil-
based PCA had a similar effect as a 0.1 μg/kg/min infusion with respect to pain control without side effects.  However, 
special attention must be given to respiratory depression.  (Korean J Anesthesiol 2010; 58: 537-541)
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Introduction
    Remifentanil is a potent, ultrashort-acting opioid with 
a predictable, rapid recovery. It also results in potentially 
rapid onset, greater postoperative pain in the immediate 
postoperative period. As postoperative pain is difficult to relieve 
once it becomes established, many investigators recommend 
that the anesthesiologist consider methods to prevent 
pain before discontinuing the remifentanil infusion when 
remifentanil is used clinically in patients who are expected to 538 www.ekja.org
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experience postoperative pain [1,2].
    One such method is to administer a long-lasting opioid before 
stopping the remifentanil during surgery. However, this might 
prolong the recovery and reduce the potential advantages 
of remifentanil [3]. Continuous remifentanil infusion at a 
lower analgesic dose postoperatively (0.05-0.23 μg/kg/min) 
is another method [4]; however, it requires postoperative 
monitoring and supervision. Few studies have evaluated the 
effect of continuous remifentanil infusion with other opioid-
based IV-patient-controlled analgesia (PCA) immediately after 
an operation. 
    We aimed to evaluate and compare the effect and safety 
of two different doses (0.05 vs. 0.1 μg/kg/min) of continuous 
remifentanil infusion immediately after an operation with 
alfentanil-based IV-PCA in patients undergoing laparoscopic-
assisted vaginal hysterectomy (LAVH).
Materials and Methods
    The study protocol was approved by our institutional review 
board and written informed consent was obtained from 
all patients before enrolling in the study. Fifty patients who 
were deemed to be American Society of Anesthesiologists 
(ASA) physical status 1 or 2, aged at least 20 years old, and 
scheduled for elective LAVH were enrolled in this study. The 
exclusion criteria were a history of alcohol or drug abuse, 
known hypersensitivity to opioids, cardiovascular or psychiatric 
disease, and chronic exposure to benzodiazepines, tricyclic 
antidepressants, or anticonvulsants.
    All patients were premedicated with midazolam 0.04 mg/
kg and glycopyrrolate 0.2 mg intramuscularly 30 minutes 
preoperatively. When the patient arrived in the operating 
room, standard monitors were placed, including the 
electrocardiogram (ECG), pulse oximetry, noninvasive blood 
pressure cuff, and bispectral index (BIS). 
    Anesthesia was induced with 4 mg/kg thiopental sodium, 
0.7 mg/kg rocuronium, and 0.1 μg/kg/min remifentanil. 
After tracheal intubation, anesthesia was maintained with 
sevoflurane-O2-air-remifentanil. The sevoflurane concentration 
and remifentanil infusion were adjusted to maintain a BIS of 
40-60 and mean arterial blood pressure (MAP) within 20% of 
the preoperative value, respectively. Twenty minutes before 
the anticipated end of surgery, ramosterone 0.15 mg was 
administered to prevent postoperative nausea and vomiting.
    At the last skin suture, the sevoflurane was discontinued, 
the neuromuscular block was reversed, and the remifentanil 
infusion dosage was changed to 0.05 μg/kg/min (group I) or 0.1 
μg/kg/min (group II). At the time of eye opening and response 
to a verbal command, all patients received IV-PCA composed 
of alfentanil 2 mg, ketorolac 150 mg, ramosterone 0.15 mg, 
and normal saline in a total volume of 100 ml. The IV-PCA 
maintenance dose, bolus dose, and lockout interval were 0.03 
ml/kg/h, 0.02 ml/kg, and 8 minutes respectively, according to 
standard practice in our unit. We did not use a loading dose for 
fear of delayed awakening.
    After obtaining adequate respiration, the patients were extu-
bated and transported to the recovery room. In the recovery 
room, all patients had an oxygen mask to aid their breathing 
(5-7 L/min). We monitored the blood pressure (BP), heart rate 
(HR), respiratory rate (RR), SpO2, and BIS at 5-minute intervals. 
Adverse effects were monitored, including muscle rigidity, 
shivering, nausea, vomiting, and respiratory depression. 
Respiratory depression was defined as SpO2 < 90% or RR < 
8 breaths/min. When respiratory depression developed, the 
remifentanil infusion and IV-PCA were discontinued. Thirty 
minutes after starting IV-PCA, the remifentanil infusion was 
discontinued. Pain was assessed using a visual analog scale 
(VAS) (0 = no pain, 100 = the worst possible pain) at 0, 5, 10, and 
30 minutes after stopping the remifentanil infusion. 
    Data are expressed as the mean ± standard deviation (SD). 
Statistical analysis was performed using SPSS (version 14.0; 
SPSS Inc., Chicago, IL, USA). The patient characteristics and 
the eye opening time in response to a verbal command were 
compared using Student’s t-test. The differences in the MAP, 
HR, BIS, SpO2, and RR between the two groups were analyzed 
using repeated-measures analysis of variance (ANOVA). In all 
tests, P < 0.05 was considered to be significant.
Results
    The two groups were comparable in terms of demographic 
data (Table 1). The BIS, MAP, and HR did not differ significantly 
between the two groups (Table 2). The eye opening times in 
response to a verbal command were 4.5 ± 3.2 vs. 6.4 ± 3.8 min 
in groups I and II, respectively. The pain scores at 0 minute 
after stopping the remifentanil infusion were lower in group 
II, and those 30 minutes after stopping were similar (Table 3). 
Side effects, such as muscle rigidity, nausea, or vomiting were 
not observed. The RR was similar between the groups (Table 4), 
although the remifentanil infusion and IV-PCA were stopped 
Table 1. Demographic Data
Group I (n = 25) Group II (n = 25)
Age (yr)
Height (cm)
Weight (kg)
Operating time (min)
   42 ± 7.5
 159 ± 5.4
57.2 ± 7.9
108.6 ± 46.2
  40.2 ± 8.6
157.2 ± 4.9
58.72 ± 8.1
        95 ± 31.4
Values are the mean ± SD. Immediately after surgery, group I re-
ceived remifentanil 0.05 µg/kg/min, and group II received remifent-
anil 0.1 µg/kg/min.539 www.ekja.org
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in the recovery room in three patients due to respiratory 
depression in group II. They were fully recovered after stopping 
the remifentanil infusion and were not administered naloxone. 
Discussion
    The purpose of this study was to compare the efficacy and 
safety of continuous remifentanil infusion at two doses (0.05 
vs. 0.1 μg/kg/min) for providing analgesia in the immediate 
postoperative period with alfentanil-based IV-PCA, which we 
have used for pain control after operations.
    A constant dose of 0.05 μg/kg/min remifentanil with alfentanil- 
based IV-PCA had an effect similar to 0.1 μg/kg/min infusion 
with respect to pain control without respiratory depression. This 
result corresponded well with those of earlier studies. Yarmush 
et al. [4] found that a 0.05-0.23 μg/kg/min remifentanil infusion 
provides safe, effective postoperative analgesia in the first 
35 minutes after extubation. Bowdle et al. [5] tried to reduce 
the infusion of remifentanil from an anesthetic dose to an 
analgesic dose (0.05 μg/kg/min) at the conclusion of surgery 
by titrating the analgesic infusion in the recovery room for 30 
minutes followed by a gradual transition to a longer-acting 
opioid. In that case, morphine was used as a rescue analgesic. 
In a previous study [6], a constant 0.1 μg/kg/min dose of remi-
fentanil provided adequate analgesia (VAS score, 1.7 ± 2.0) in 
78% of patients without signs of respiratory depression after 
a 4-hour infusion. That study used meperidine 0.5 mg/kg as a 
rescue analgesic. They suggested that a 2-4 hour remifentanil 
Table 2. Changes in the BIS, HR, and MAP
BIS HR MAP
Group I
(n = 25)
Group II
(n = 25)
Group I
(n = 25)
Group II
(n = 25)
Group I
(n = 25)
Group II
(n = 25)
TSS
TSE
TEO
TE
TRR0
TRR5
TRR10
TRR15
TR0
TR5
TR10
48.3 ± 9.9
  66.6 ± 11.9
82.8 ± 5.6
85.3 ± 5.5
84.8 ± 5.2
85.5 ± 5.2
86.9 ± 5.7
87.1 ± 4.1
87.1 ± 3.9
87.5 ± 6.1
88.2 ± 5.8
52.3 ± 6.0
  67.4 ± 10.1
83.0 ± 6.7
87.9 ± 5.8
88.9 ± 5.6
88.4 ± 4.3
88.3 ± 5.5
89.0 ± 6.6
87.7 ± 5.6
90.5 ± 4.7
91.2 ± 4.6
68.4 ± 12.0
77.2 ± 19.9
98.7 ± 15.7
101.2 ± 14.8
84.7 ±15.6
76.0 ± 12.3
71.8 ± 12.1
70.9 ± 12.5
70.9 ± 12.8
70.7 ± 12.7
71.9 ± 12.9
 66 ± 9.9
70.9 ± 13.8
95.8 ± 13.8
103.1 ± 15.9
89.9 ± 15.9
80.8 ± 15.7
 75.9 ±13.9
   75 ± 14.6
73.1 ± 12.9
71.5 ± 10.2
75.5 ± 11.1
88.5 ± 13.2
94.8 ± 19.5
107 ±17.5
110.8 ± 15.2
97.4 ± 14.8
95.0 ±13.7
95.6 ± 15.9
96.7 ± 14.5
93.5 ± 13.8
96.2 ± 12.9
95.8 ± 13.8
86.5 ± 9.9
86.9 ± 13.6
101.8 ± 15.5
 112 ± 16.5
99.2 ± 10.2
95.2 ± 14.9
95.7 ± 14.6
92.2 ± 13.9
89.4 ± 12.9
91.9 ± 12.5
96.5 ± 13.8
Values are the mean ± SD. Immediately after surgery, group I received remifentanil 0.05 µg/kg/min and group II received remifentanil 0.1 µg/
kg/min. BIS: bispectral index, HR: heart rate, MAP: mean arterial blood pressure, TSS: at the time of starting to suture the skin, TSE: ending skin 
suture, TEO: eye opening time, TE: extubation, TRR0, TRR5, TRR10, and TRR15: 0, 5, 10, and 15 minutes, respectively, after arriving in the recovery room, 
TR0, TR5, and TR10: 0, 5, and 10 min, respectively, after stopping the remifentanil infusion. No differences were observed between the two groups. 
Table 3. Visual Analog Pain Score
TR0 TR5 TR10 TR30
Group I (n = 25)
Group II (n = 25)
62.4 ± 30.7
    55 ± 30.2
66.4 ± 26.4
55.9 ± 26.8
65.2 ± 27.1
57.3 ± 24.5
    42 ± 16.6
43.2 ± 15.2
Values are the mean ± SD. Immediately after surgery, group I received remifentanil 0.05 µg/kg/min, and group II received remifentanil 0.1 µg/
kg/min. TR0, TR5, TR10, and TR30: 0, 5, 10, and 30 minutes, respectively, after stopping the remifentanil infusion. No differences were found be-
tween the two groups.
Table 4. Respiratory Rate in the Recovery Room
TRR0 TRR5 TRR10 TRR15 TR0 TR5 TR10
Group I (n = 25)
Group II (n = 25)
20.2 ± 5.0
20.8 ± 6.2
17.8 ± 4.4
17.4 ± 4.8
16.7 ± 4.1
    17 ± 5.8
16.6 ± 5.1
15.5 ± 5.4
15.8 ± 4.2
15.4 ± 4.9
17.0 ± 2.9
16.1 ± 4.7
17.3 ± 2.6
16.8 ± 4.7
Values are the mean ± SD. Immediately after surgery, group I received remifentanil 0.05 µg/kg/min, and group II received remifentanil 0.1 µg/
kg/min. TRR0, TRR5, TRR10, and TRR15: 0, 5, 10, and15 minutes, respectively, after arriving in the recovery room, TR0, TR5, and TR10: 0, 5, and 10 min-
utes, respectively, after stopping the remifentanil infusion. No differences were observed between the two groups.540 www.ekja.org
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infusion in the immediate postoperative period was adequate 
for ensuring patient adaptation to other analgesics, which 
proved difficult to initiate within 1 hour. The remifentanil 
infusion duration and the drug and method for rescue analgesia 
were variables in each study. We thought that the duration 
of remifentanil infusion for the analgesic dose in the current 
study provided enough transition time before discontinuing 
the remifentanil infusion [2,4]. Additional studies are needed 
to define a transition regimen that will improve postoperative 
analgesia in patients who received a remifentanil infusion 
during an operation. 
    The incidence of respiratory depression is variable [4,5,7]. 
Bowdle et al. [5] reported that adverse respiratory events (SpO2 
< 90% or RR < 12) affected 29% of patients and the incidence 
of apnea was 7%. Schüttler et al. [7] reported apnea in 11% and 
respiratory depression in 10%. In our study, 3 of the 25 patients 
given the 0.1 μg/kg/min remifentanil infusion developed 
respiratory depression. These patients recovered soon after 
the remifentanil infusion and IV-PCA was stopped. The causes 
for the increased incidence of respiratory depression may be 
the different method of remifenanil infusion rate increments 
according to VAS, the addition of bolus or not, or the use of 
other rescue analgesics or not.
    Some studies have suggested that remifentanil infusion 
during surgery results in acute opioid tolerance or hyperalgesia 
manifested as increased postoperative pain and the need 
for opioids [4,8]. However, acute opioid tolerance and its 
prevention remain controversial [9]. Patients treated with 
remifentanil infusion might suffer from more postoperative pain 
during the immediate postoperative period [10]. Postoperative 
pain is difficult to relieve, especially once it has become 
established [5]. A study has suggested that anesthesiologists 
who use remifentanil as the opioid component of anesthesia 
must anticipate this rapid onset of pain and provide analgesia 
appropriate for the degree of anticipated postoperative pain 
before discontinuing a remifentanil infusion [4].
    Continuing the remifentanil infusion at a lower, analgesic 
dose immediately after an operation is effective for pain control, 
but a need to switch to long-acting analgesics still exists before 
leaving the postanesthetic care unit [4]. In this study, alfentanil-
based IV-PCA was provided after eye opening in response 
to a verbal command, and a loading dose of PCA or other 
analgesics was not allowed. Upon stopping the remifentanil 
infusion, the pain score was 62.4 ± 30 in group I and 55 ± 30.2 
in group II. These scores were similar to the results of studies 
that used morphine or meperidine as rescue analgesics and 
comparable to those of reports that evaluated pain control after 
LAVH with IV-PCA [6,11]. Most patients remained calm and did 
not complain of pain. We expected a slightly lower pain score, 
but no significant differences were observed between the two 
groups. When considering the side effects, such as respiratory 
depression, the 0.1 μg/kg/min remifentanil infusion showed no 
advantages compared to 0.05 μg/kg/min.
    A recent clinical study has suggested that remifentanil infusion 
should not be continued immediately postoperatively, but be 
given in the form of remifentanil PCA. However, the safety of 
remifentanil in awake and spontaneously breathing patients 
during the postoperative period has not been established and 
the efficacy and safety of remifentanil PCA are controversial. 
Krishnan et al. [12] reported that continuing with remifentanil 
PCA may be considered for patients who receive a remifentanil 
infusion as a part of anesthesia during surgery. However, 
special attention must be given to respiratory depression when 
establishing remifentanil PCA and any remifentanil bolus 
should be administered only in a controlled fashion and slowly 
to avoid potential respiratory and cardiovascular side effects. 
Some studies have reported that remifentanil PCA has no 
benefits compared to fentanyl or morphine [13,14]. Moreover, 
it is not safe for postoperative analgesia in the general ward, 
and careful monitoring of respiratory function and skills in the 
recognition and treatment of inadequate respiration should be 
obligatory in a clinical setting when using remifentanil [5,13]. 
The high cost of remifentanil might also be a considering factor. 
    In conclusion, a continuous remifentanil infusion (0.05 μg/
kg/min) immediately postoperatively with alfentanil-based 
IV-PCA had a similar effect as a 0.1 μg/kg/min infusion with 
respect to pain control and respiratory depression.
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